PropertyValue
?:abstract
  • A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.xcrm.2020.100145
?:journal
  • Cell_Rep_Med
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/ecc48e34f0e048547aa048ee49985feeebc8a60e.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7670931.xml.json
?:pmcid
?:pmid
?:pmid
  • 33225317.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
?:type
?:year
  • 2020-11-17

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/yqfnvnq2>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/yqfnvnq2>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all